CD274 and colorectal cancer: Amongst the landscape of ICI, the Chinese National Medical Products Administration (NMPA) granted marketing authorization to Envafolimab, the world's first single-domain PD-L1 antibody formulated for subcutaneous injection, as a second-line or further monotherapy treatment option for dMMR/MSI-H solid tumors, including advanced colorectal cancer, based on a pivotal phase 2 study [25,26].